STTR Phase I: Improved drug delivery platforms for localized and sustained drug deposition for traumatic injuries

STTR 第一阶段：改进的药物输送平台，用于创伤性损伤的局部和持续药物沉积

• 批准号: 2136542
• 负责人: Jelena Jeremic
• 金额: $ 25.6万
• 依托单位: NOSTOPHARMA, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136542&HistoricalAwards=false
• 关键词: STTR; Phase; Improved; drug; delivery

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project seeks to reduce complications due to trauma. Current traumatic injury treatments are systemic and untargeted with unwanted side effects and low efficacy. The proposed project will develop a sustained-release, biodegradable, nanoparticle drug delivery system for treatment of soft tissue trauma complications. The successful commercialization of this technology may advance the state of the art in sustained release technologies and dramatically improve the standard of care for trauma patients by addressing critical needs to enhance medication compliance, as well as the efficacy and safety of medications prescribed following trauma surgery. This Small Business Technology Transfer (STTR) Phase I project will address the needs to improve traumatic injury treatments through the development of a sustained-release, biodegradablem drug delivery platform that delivers post traumatic medications within the injured tissue thereby obviating the need for unnecessary systemic drug administration. Such a technology has the potential to improve the clinical outcomes of surgical procedures for patients with post traumatic injuries and reduce societal costs associated with additional surgeries and rehabilitation among trauma surgery patients. In addition, it is anticipated that this drug-device combination will reduce surgery times, save money, and prevent complications among affected patients. During Phase I, the team proposes to demonstrate in vitro and in vivo feasibility towards altering the ectopic bone microenvironment with the aid of nanotechnology that will prevent ectopic bone development and progression. The technology uses immunomodulatory nanoparticles loaded with the Hedgehog pathway inhibitor.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业技术转让（STTR）第一阶段项目的更广泛的影响/商业潜力旨在减少创伤引起的并发症。目前的创伤性损伤治疗是全身性的和非靶向的，具有不希望的副作用和低疗效。该项目将开发一种缓释、可生物降解的纳米颗粒药物输送系统，用于治疗软组织创伤并发症。该技术的成功商业化可以推进持续释放技术的最新技术水平，并通过解决关键需求来提高药物依从性以及创伤手术后处方药物的有效性和安全性，从而显著提高创伤患者的护理标准。该小企业技术转让（STTR）第一阶段项目将通过开发一种缓释、可生物降解的药物输送平台来满足改善创伤性损伤治疗的需求，该平台可在受伤组织内输送创伤后药物，从而避免不必要的全身给药。这种技术有可能改善创伤后损伤患者的外科手术的临床结果，并降低与创伤手术患者的额外手术和康复相关的社会成本。此外，预计这种药物-器械组合将减少手术时间，节省资金，并预防受影响患者的并发症。在第一阶段，研究小组建议在体外和体内证明在纳米技术的帮助下改变异位骨微环境的可行性，这将防止异位骨的发育和进展。 该技术使用了载有Hedgehog通路抑制剂的免疫调节纳米颗粒。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。